reports
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Co...
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update -- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases ...
Synaptics Reports Fourth Quarter and Full Year Fiscal 2025 Results
Synaptics Reports Fourth Quarter and Full Year Fiscal 2025 Results Fiscal 2025 revenue grew 12.0%, fueled by 53% growth in Core IoT product sales Synaptics' Board of Directors approved a new share repurchase program of up to $150 million Fiscal 2025 Financial Highlights Revenue of $1.074 billion increased 12% year-over-yearCore IoT product sales grew by 53% year-over-yearGAAP loss per share of $1.22Non-GAAP diluted earnings per share increased 61% to $3.62Repurchased $128 million (or approximately 1.8 million) sharesReduced gross debt by approximately 14% or $134 million Q4’25 Financial...
Appian Announces Second Quarter 2025 Financial Results
Appian Announces Second Quarter 2025 Financial Results Second quarter cloud subscriptions revenue increased 21% year-over-year to $106.9 million Second quarter total revenue increased 17% year-over-year to $170.6 million MCLEAN, Va., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the second quarter ended June 30, 2025. “Appian AI drove strong financial results in the second quarter of 2025, with higher prices and a larger pipeline,” said Matt Calkins, CEO & Founder. Second Quarter 2025 Financial Highlights: Revenue: Cloud subscriptions r...
Synaptics To Participate at Upcoming Investor Conference Monday, Augus...
Synaptics To Participate at Upcoming Investor Conference Monday, August 11, 2025 SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced its participation in the upcoming investor conference. Rahul Patel, President & Chief Executive Officer, and Ken Rizvi, CFO, will present at the KeyBanc Capital Markets’ Technology Leadership Forum on Monday, August 11, 2025, at 10:00 AM PT. To view the webcast or access a replay, please visit About Synaptics Incorporated: Synaptics (Nasdaq: ) is driving innovation in AI at the Edge, bringing AI close...
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtua...
KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on Wednesday, August 13, 2025. A pre-recorded presentation will be made available beginning on Wednesday, August 13, ...
Appian To Participate in Upcoming Investor Conferences
Appian To Participate in Upcoming Investor Conferences MCLEAN, Va., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN), the leading platform for AI process automation, announced today that management will be presenting and hosting meetings with institutional investors at the following upcoming conferences: Keybanc Technology Leadership ForumMonday August 11, 2025A fireside chat is scheduled for 2:00pm Mountain Time and will be webcast live at the following link: Citi Global TMT ConferenceWednesday September 3, 2025A fireside chat is scheduled for 12:50pm Eastern Time and will ...
Amicus Therapeutics Announces Second Quarter 2025 Financial Results an...
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold® Q2 Revenue of $128.9M, up 12% at CER Pombiliti® + Opfolda® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, tod...
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results ...
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2025. Participants and investors interested in accessing the call by phone will need to register using the . After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event...
Synaptics to Report Fourth Quarter and Full Year Fiscal 2025 Results o...
Synaptics to Report Fourth Quarter and Full Year Fiscal 2025 Results on August 7, 2025 SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (Nasdaq: ) today announced that it will report financial results for the fourth quarter and full year of fiscal 2025 on Thursday, August 7, 2025, after the market closes. The Company will host a corresponding conference call for analysts and investors at 2:00 p.m. PT (5:00 p.m. ET), to discuss the results. To participate on the live call, analysts and investors should pre-register at . Registrants will receive ...
Appian To Announce Second Quarter 2025 Financial Results on August 7, ...
Appian To Announce Second Quarter 2025 Financial Results on August 7, 2025 MCLEAN, Va., July 10, 2025 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) today announced that it will release financial results for the second quarter ended June 30, 2025 before the U.S. financial markets open on Thursday, August 7, 2025. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, participants can join the call, usi...
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Ev...
KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) -- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and...
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the...
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss the potential of KPI-012 for the treatment of persistent corneal epithelial defect (P...
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase ...
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in Japan for Adults with Late-onset Pompe Disease (LOPD) PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD). "We are delighted that we will now be able to offer a compel...
- Jonathan Moreland
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MTH MERITAGE HOMES CORPORATION
INUV INUVO INC
FFIN FIRST FINANCIAL BANKSHARES INC
CAL CALERES INC.
CABO CABLE ONE INC.
PATK PATRICK INDUSTRIES INC.
ADC AGREE REALTY CORPORATION
TTI TETRA TECHNOLOGIES INC.
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
CC CHEMOURS CO.
IOVA IOVANCE BIOTHERAPEUTICS INC
QTRX QUANTERIX CORPORATION
RSSS RESEARCH SOLUTIONS
BHC BAUSCH HEALTH COMPANIES INC.
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
ETON ETON PHARMACEUTICALS
IMUX IMMUNIC INC
BLDR BUILDERS FIRSTSOURCE
FNWB INC.
AMPY FIRST NORTHWEST BANCORP
DCTH AMPLIFY ENERGY
ENX DELCATH SYSTEMS
TSHA EATON VANCE NEW YORK MUNICIPAL BOND FUND
SMMT TAYSHA GENE THERAPIES
HLMN SUMMIT THERAPEUTICS INC
COOK HILLMAN SOLUTIONS CORP.
AIRS TRAEGER
GECC INC.
TYRA AIRSCULPT TECHNOLOGIES INC
NNUP GREAT ELM CAPITAL CORP
BHRB TYRA BIOSCIENCES INC
DPG NOCOPI TECHS INC
RNXT BURKE & HERBERT BANK & TR/VA
GTE DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK RENOVORX INC
NKGN GRAN TIERRA ENERGY INC.
MNR SR BANCORP INC
NBBK NKGEN BIOTECH INC
NCDL MACH NATURAL RESOURCES LP
SDHY NB BANCORP INC.
ABL NUVEEN CHURCHILL DIRECT LENDING CORP
WHLR PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
ABACUS GLOBAL MANAGEMENT INC.
WHEELER REAL ESTATE INVESTMENT TRUST INC.
- Jonathan Moreland
PLUG PLUG POWER INC.
PBF PBF ENERGY INC. CLASS A
BRKR BRUKER CORPORATION
UEIC UNIVERSAL ELECTRONICS INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BRT BRT APARTMENTS
QTRX QUANTERIX CORPORATION
RFL RAFAEL HOLDINGS CL B
BBDC BARINGS BDC INC.
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
DLHC DALEIGH HOLDINGS CORP
RNXT RENOVORX INC
- Jonathan Moreland
WSR WHITESTONE REIT
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MCY MERCURY GENERAL CORPORATION
FLO FLOWERS FOODS INC.
CTBI COMMUNITY TRUST BANCORP INC.
BUSE FIRST BUSEY CORPORATION
PATK PATRICK INDUSTRIES INC.
VFF VILLAGE FARMS INTERNATIONAL IN
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
CIA CITIZENS INC. CL A
BDL FLANIGAN'S ENTERPRISES INC.
CC CHEMOURS CO.
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
RSSS RESEARCH SOLUTIONS
RFL RAFAEL HOLDINGS CL B
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
REZI RESIDEO TECHNOLOGIES
IMUX INC.
FNWB IMMUNIC INC
XRX FIRST NORTHWEST BANCORP
AMPY XEROX HOLDINGS CORPORATION
VLA AMPLIFY ENERGY
TSHA ARBOR METALS
INNV TAYSHA GENE THERAPIES
SMMT INNOVAGE HOLDING
AFBI SUMMIT THERAPEUTICS INC
COOK AFFINITY BANCSHARES
TYRA INC.
BHRB TRAEGER
DPG INC.
VFC TYRA BIOSCIENCES INC
UHG BURKE & HERBERT BANK & TR/VA
GENK DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK VF CORPORATION
NKGN UNITED HOMES GROUP INC
NCDL GEN RESTAURANT GROUP INC
SDHY SR BANCORP INC
NEO NKGEN BIOTECH INC
JEQ NUVEEN CHURCHILL DIRECT LENDING CORP
LION PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
SLS NEO CORPORATE PUBLIC COMPANY LIMITED
ABL THE JAPAN EQUITY FUND
INC.
LIONSGATE STUDIOS CORP
SELLAS LIFE SCIENCES GROUP INC
ABACUS GLOBAL MANAGEMENT INC.
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PEB PEBBLEBROOK HOTEL TRUST
MG MISTRAS GROUP
ELY CALLAWAY GOLF COMPANY
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
MPB MID PENN BANCORP INC.
RSSS RESEARCH SOLUTIONS
BBDC BARINGS BDC INC.
AMPY AMPLIFY ENERGY
COOK TRAEGER
STGW INC.
TYRA STAGWELL INC
NCDL TYRA BIOSCIENCES INC
ABL NUVEEN CHURCHILL DIRECT LENDING CORP
ABACUS GLOBAL MANAGEMENT INC.
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (mig...
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve PRINCETON, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat (cipa+mig) in adults with late-onset Pompe disease (LOPD) in . In this new publication, based on a within group effect-size analysis, subjects who switched from alglucosidase alfa to cipa+mig achieved improvements or stability in most of the outcomes measured. ...
- Jonathan Moreland
SON SONOCO PRODUCTS COMPANY
NCR NCR CORPORATION
UNH UNITEDHEALTH GROUP INCORPORATED
RYAM RAYONIER ADVANCED MATERIALS INC
PLUG PLUG POWER INC.
PENN PENN NATIONAL GAMING INC.
PEB PEBBLEBROOK HOTEL TRUST
OEC ORION ENGINEERED CARBONS SA
MTX MINERALS TECHNOLOGIES INC.
MTDR MATADOR RESOURCES COMPANY
MO ALTRIA GROUP INC
LGND LIGAND PHARMACEUTICALS INCORPORATED
JRVR JAMES RIVER GROUP HOLDINGS LTD
HUN HUNTSMAN CORPORATION
HUM HUMANA INC.
ASB ASSOCIATED BANC-CORP
NEWT NEWTEK BUSINESS SERVICES INC.
RLMD RELMADA THERAPEUTICS
VFF VILLAGE FARMS INTERNATIONAL IN
HTLD HEARTLAND EXPRESS INC.
VSH VISHAY INTERTECHNOLOGY INC.
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
BXC BLUELINX HOLDINGS
GBLI GLOBAL INDEMNITY PLC
AMBC AMBAC FINANCIAL GROUP INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CARS CARS.COM INC.
BRT BRT APARTMENTS
SNBR SLEEP NUMBER CORPORATION
MBIN MERCHANTS BANCORP
PMTS CPI CARD GROUP
LILA LIBERTY LATIN AMERICA A
COLD AMERICOLD REALTY TRUST
BBDC BARINGS BDC INC.
UTGN UTG
RPAY REPAY HOLDINGS (A)
XRX XEROX HOLDINGS CORPORATION
VLA ARBOR METALS
ONEW ONEWATER MARINE
MTCH MATCH GROUP INC.
PRG PROG HOLDINGS
MINM INC.
CIVI MINIM
UDMY INC.
OGN CIVITAS RESOURCES INC
OPAL UDEMY INC
PRME ORGANON & CO
VFC OPAL FUELS INC
PHIN PRIME MEDICINE INC
NCDL VF CORPORATION
FIP PHINIA INC
FG NUVEEN CHURCHILL DIRECT LENDING CORP
HCWB FTAI INFRASTRUCTURE INC
NEO F AND G ANNUITIES AND LIFE
INC.
HCW BIOLOGICS INC
NEO CORPORATE PUBLIC COMPANY LIMITED
Amicus Therapeutics to Present at Upcoming Investor Conferences in Jun...
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at 11:40 a.m. ETGoldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL, on Tuesday, June 10, 2025, at 2:00 p.m. ET A live audio webcast of each presentation can also be accessed via the investors sectio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.